Research Article
BibTex RIS Cite
Year 2024, Volume: 41 Issue: 1, 152 - 154, 29.03.2024

Abstract

References

  • Stroebe H. Ueber Entstehung und Bau der Gehirngliome. Beitr Path Anat, 1895;18: 405-486.
  • Doddamani RS, Meena RK, Selvam MM, Venkataramanaa NK, Tophkhane M, Garg SK.. Intraventricular gliosarcomas: literature review and a case description. World Neurosurgery, 2016;90:707. e705-707. e712
  • Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta neuropathologica, 2016;131:803-820
  • Din NU, Ishtiaq H, Rahim S, Abdul-Ghafar J, Ahmad Z. Gliosarcoma in patients under 20 years of age. A clinicopathologic study of 11 cases and detailed review of the literature. BMC pediatrics, 2021;21:1-10
  • Actor B, Cobbers JL, Büschges R, Wolter M, Knobbe CB, Reifenberger G, et al. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes, Chromosomes and Cancer, 2002;34:416-427
  • Wang X, Jiang J, Liu M, You C. Treatments of gliosarcoma of the brain: a systematic review and meta-analysis. Acta Neurologica Belgica, 2021;121:1789-1797
  • Kozak KR, Mahadevan A, Moody JS Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro-oncology, 2009;11: 183-191
  • Yi X, Cao H, Tang H, Gong G, Hu Z, Liao W, et al. Gliosarcoma: a clinical and radiological analysis of 48 cases. European Radiology, 2019;29: 429-438
  • Rath G, Sharma D, Mallick S, Gandhi A, Joshi N, Haresh K, et al. Clinical outcome of patients with primary gliosarcoma treated with concomitant and adjuvant temozolomide: A single institutional analysis of 27 cases. Indian Journal of Cancer, 2015;52:599-603
  • Vukelić Ž, Kalanj-Bognar S, Froesch M, Bîndilă L, Radić B, Allen M, et al. Human gliosarcoma-associated ganglioside composition is complex and distinctive as evidenced by high-performance mass spectrometric determination and structural characterization. Glycobiology, 2007;17:504-515
  • Kumar P, Singh S, Kumar P, Krishnani N, Datta NR. Gliosarcoma: an audit from a single institution in India of 24 post-irradiated cases over 15 years. Journal of Cancer Research and Therapeutics, 2008;4: 164-168.
  • Han SJ, Yang I, Tihan T, Prados MD, Parsa AT. Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. Journal of Neuro-Oncology, 2010;96:313-320.
  • Walker GV, Gilbert MR, Prabhu SS, Brown PD, McAleer MF. Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. Journal of Neuro-oncology, 2013;112: 83-89
  • Narendra K, Bhattacharyya T, Karan C, Shalunke P, Radotra B, Yadav BS. Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience. South Asian Journal of Cancer, 2015;4: 015-017
  • Weaver D, Vandenberg S, Park T, Jane JA. Selective peripancreatic sarcoma metastases from primary gliosarcoma: case report. Journal of Neurosurgery, 1984;61:599-601
  • Reis RM, Könü-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H. Genetic profile of gliosarcomas. The American Journal of Pathology, 2000;156 : 425-432
  • Damodaran O, van Heerden J, Nowak AK, Bynevelt M, Mcdonald K, Marsh J, et al. Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy. Journal of Clinical Neuroscience, 2014;21: 478-481.

A rare variant of glioblastoma is gliosarcoma: 11-case clinical trial

Year 2024, Volume: 41 Issue: 1, 152 - 154, 29.03.2024

Abstract

Gliosarcoma is a rare subtype of glioblastoma, IDH wild type. Its characteristic features are a biphasic configuration with mixed glial and mesenchymal components. Here in, we present a rare case of Gliosarcoma that has been operated in our clinic in the last 10 years. Patients with gliosarcoma pathology results were collected from the ones operated in our faculty within 10 years. Patients from all age groups were included in the study. 1 of 11 gliosarcoma cases was described in detail. Seven of the cases were male, while 4 were female. Regarding tumor location, six 6 were located in the right, while 5 were in the left hemisphere. The average survival time of all 11 patients was 11 months. In 6 cases, the initial pathologic diagnosis was gliosarcoma, while in 5 cases, it was glioblastoma, and in the 2nd case, the pathology result was gliosarcoma. Gliosarcomas have a worse prognosis in terms of survival. Clinically, it is not possible to distinguish between glioblastomas and gliosarcomas. Treatment proceeds in the same way.

References

  • Stroebe H. Ueber Entstehung und Bau der Gehirngliome. Beitr Path Anat, 1895;18: 405-486.
  • Doddamani RS, Meena RK, Selvam MM, Venkataramanaa NK, Tophkhane M, Garg SK.. Intraventricular gliosarcomas: literature review and a case description. World Neurosurgery, 2016;90:707. e705-707. e712
  • Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta neuropathologica, 2016;131:803-820
  • Din NU, Ishtiaq H, Rahim S, Abdul-Ghafar J, Ahmad Z. Gliosarcoma in patients under 20 years of age. A clinicopathologic study of 11 cases and detailed review of the literature. BMC pediatrics, 2021;21:1-10
  • Actor B, Cobbers JL, Büschges R, Wolter M, Knobbe CB, Reifenberger G, et al. Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes, Chromosomes and Cancer, 2002;34:416-427
  • Wang X, Jiang J, Liu M, You C. Treatments of gliosarcoma of the brain: a systematic review and meta-analysis. Acta Neurologica Belgica, 2021;121:1789-1797
  • Kozak KR, Mahadevan A, Moody JS Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro-oncology, 2009;11: 183-191
  • Yi X, Cao H, Tang H, Gong G, Hu Z, Liao W, et al. Gliosarcoma: a clinical and radiological analysis of 48 cases. European Radiology, 2019;29: 429-438
  • Rath G, Sharma D, Mallick S, Gandhi A, Joshi N, Haresh K, et al. Clinical outcome of patients with primary gliosarcoma treated with concomitant and adjuvant temozolomide: A single institutional analysis of 27 cases. Indian Journal of Cancer, 2015;52:599-603
  • Vukelić Ž, Kalanj-Bognar S, Froesch M, Bîndilă L, Radić B, Allen M, et al. Human gliosarcoma-associated ganglioside composition is complex and distinctive as evidenced by high-performance mass spectrometric determination and structural characterization. Glycobiology, 2007;17:504-515
  • Kumar P, Singh S, Kumar P, Krishnani N, Datta NR. Gliosarcoma: an audit from a single institution in India of 24 post-irradiated cases over 15 years. Journal of Cancer Research and Therapeutics, 2008;4: 164-168.
  • Han SJ, Yang I, Tihan T, Prados MD, Parsa AT. Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. Journal of Neuro-Oncology, 2010;96:313-320.
  • Walker GV, Gilbert MR, Prabhu SS, Brown PD, McAleer MF. Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. Journal of Neuro-oncology, 2013;112: 83-89
  • Narendra K, Bhattacharyya T, Karan C, Shalunke P, Radotra B, Yadav BS. Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience. South Asian Journal of Cancer, 2015;4: 015-017
  • Weaver D, Vandenberg S, Park T, Jane JA. Selective peripancreatic sarcoma metastases from primary gliosarcoma: case report. Journal of Neurosurgery, 1984;61:599-601
  • Reis RM, Könü-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H. Genetic profile of gliosarcomas. The American Journal of Pathology, 2000;156 : 425-432
  • Damodaran O, van Heerden J, Nowak AK, Bynevelt M, Mcdonald K, Marsh J, et al. Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy. Journal of Clinical Neuroscience, 2014;21: 478-481.
There are 17 citations in total.

Details

Primary Language English
Subjects Brain and Nerve Surgery (Neurosurgery)
Journal Section Research Article
Authors

Recai Engin 0000-0003-2957-9848

Fatih Tomakin 0000-0001-8290-2216

Gürkan Gökalp 0009-0000-5151-726X

Mustafa Aras 0000-0002-8360-148X

Cengiz Cokluk 0000-0003-2146-3621

Publication Date March 29, 2024
Submission Date January 22, 2024
Acceptance Date March 11, 2024
Published in Issue Year 2024 Volume: 41 Issue: 1

Cite

APA Engin, R., Tomakin, F., Gökalp, G., Aras, M., et al. (2024). A rare variant of glioblastoma is gliosarcoma: 11-case clinical trial. Journal of Experimental and Clinical Medicine, 41(1), 152-154.
AMA Engin R, Tomakin F, Gökalp G, Aras M, Cokluk C. A rare variant of glioblastoma is gliosarcoma: 11-case clinical trial. J. Exp. Clin. Med. March 2024;41(1):152-154.
Chicago Engin, Recai, Fatih Tomakin, Gürkan Gökalp, Mustafa Aras, and Cengiz Cokluk. “A Rare Variant of Glioblastoma Is Gliosarcoma: 11-Case Clinical Trial”. Journal of Experimental and Clinical Medicine 41, no. 1 (March 2024): 152-54.
EndNote Engin R, Tomakin F, Gökalp G, Aras M, Cokluk C (March 1, 2024) A rare variant of glioblastoma is gliosarcoma: 11-case clinical trial. Journal of Experimental and Clinical Medicine 41 1 152–154.
IEEE R. Engin, F. Tomakin, G. Gökalp, M. Aras, and C. Cokluk, “A rare variant of glioblastoma is gliosarcoma: 11-case clinical trial”, J. Exp. Clin. Med., vol. 41, no. 1, pp. 152–154, 2024.
ISNAD Engin, Recai et al. “A Rare Variant of Glioblastoma Is Gliosarcoma: 11-Case Clinical Trial”. Journal of Experimental and Clinical Medicine 41/1 (March 2024), 152-154.
JAMA Engin R, Tomakin F, Gökalp G, Aras M, Cokluk C. A rare variant of glioblastoma is gliosarcoma: 11-case clinical trial. J. Exp. Clin. Med. 2024;41:152–154.
MLA Engin, Recai et al. “A Rare Variant of Glioblastoma Is Gliosarcoma: 11-Case Clinical Trial”. Journal of Experimental and Clinical Medicine, vol. 41, no. 1, 2024, pp. 152-4.
Vancouver Engin R, Tomakin F, Gökalp G, Aras M, Cokluk C. A rare variant of glioblastoma is gliosarcoma: 11-case clinical trial. J. Exp. Clin. Med. 2024;41(1):152-4.